The listings featured on this site are from companies from which this site receives compensation. This influences where, how and in what order such listings appear on this site.
Last Updated: Jun 2026
01
Exclusive: $140 Off + Free Shipping
02
03
Exclusive Promotion
04
05
06
07
08
09
10
Our Top Choice
01
Exclusive: $140 Off + Free Shipping
01
Exclusive: $140 Off + Free Shipping
02
03
Exclusive Promotion
04
05
06
07
08
09
10
01
Exclusive: $140 Off + Free Shipping
Zepbound® is the brand of tirzepatide the FDA approved in November 2023 for chronic weight management. It is a once-weekly injection for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition, prescribed together with a reduced-calorie diet and increased physical activity.
What sets it apart mechanically: per the FDA, tirzepatide activates receptors for two intestinal hormones — GLP-1 and GIP — that together reduce appetite and food intake. Treatment is titrated upward over 4 to 20 weeks to a maintenance dose of 5, 10, or 15 mg weekly.
All three contain or claim to contain tirzepatide, but they are not interchangeable on paper:
Zepbound®'s approval rests on two 72-week placebo-controlled trials totaling about 3,500 participants. In the larger trial of adults without diabetes — average starting weight 231 pounds — people on the highest dose lost an average of 18% of body weight relative to placebo, per the FDA. The SURMOUNT-1 results behind that figure: 15.0%, 19.5%, and 20.9% average reductions on 5, 10, and 15 mg respectively, versus 3.1% on placebo.
Extended follow-up also recorded weight regain after participants stopped treatment. Plan for the maintenance phase before you start, not after.
Zepbound® pricing varies by dose, pharmacy, insurance, and manufacturer savings programs — and telehealth programs layer their own membership or visit fees on top. The advertised first-month price is rarely the steady-state price.
Before committing, get three numbers in writing: the monthly cost at your likely maintenance dose (not just the starting dose), what the program charges for provider visits and follow-ups, and what happens to billing if you pause treatment. A provider that cannot answer those plainly is telling you something.
From the FDA's approval announcement: Zepbound® should not be used by people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. It has not been studied in people with a history of pancreatitis or severe gastrointestinal disease, and it carries warnings involving the pancreas, gallbladder, kidneys, blood sugar, diabetic retinopathy, and suicidal behavior or thinking.
Common side effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, injection-site reactions, fatigue, and reflux. A legitimate telehealth provider screens for all of this in the intake — treat a thin questionnaire as a red flag.
Use the chart above to shortlist, then compare where programs actually differ: brand-name versus compounded supply, dose-level pricing, refill reliability during the titration months, and whether you can message a clinician when side effects show up at a dose increase.
If you have insurance, check coverage for brand-name Zepbound® before paying cash anywhere — some programs will run that check for you at no cost.
Shortlist two or three companies above, read their full reviews, and confirm maintenance-dose pricing, pharmacy source, and clinician access before your online visit.
Sources used for medical context
How We Rank
Learn more about how comparetreatments.com rankings are determined.
Frequently Asked Questions (FAQ)